BTIG Research Issues Pessimistic Forecast for LifeMD (NASDAQ:LFMD) Stock Price

LifeMD (NASDAQ:LFMD) had its price target reduced by analysts at BTIG Research from $18.00 to $10.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price target indicates a potential upside of 111.42% from the company’s current price.

A number of other research firms also recently issued reports on LFMD. HC Wainwright decreased their price target on shares of LifeMD from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. KeyCorp decreased their target price on LifeMD from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Wednesday, August 6th. Zacks Research upgraded LifeMD from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Wall Street Zen cut LifeMD from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of LifeMD in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, LifeMD presently has a consensus rating of “Moderate Buy” and an average target price of $11.83.

LifeMD Stock Performance

Shares of LFMD stock opened at $4.73 on Tuesday. The firm has a market capitalization of $224.30 million, a price-to-earnings ratio of -22.52 and a beta of 1.57. The stock has a fifty day moving average of $6.05 and a 200 day moving average of $8.71. LifeMD has a 52 week low of $4.13 and a 52 week high of $15.84. The company has a quick ratio of 0.72, a current ratio of 0.77 and a debt-to-equity ratio of 9.21.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings data on Monday, November 17th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The business had revenue of $47.28 million for the quarter, compared to analyst estimates of $62.07 million. During the same period in the previous year, the business earned $0.09 EPS. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts expect that LifeMD will post -0.56 earnings per share for the current year.

Insider Transactions at LifeMD

In other LifeMD news, insider Nicholas P. Alvarez sold 75,000 shares of the business’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $5.92, for a total value of $444,000.00. Following the sale, the insider directly owned 605,000 shares of the company’s stock, valued at approximately $3,581,600. The trade was a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 18.40% of the company’s stock.

Hedge Funds Weigh In On LifeMD

Large investors have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd bought a new stake in LifeMD during the 2nd quarter valued at about $818,000. Acadian Asset Management LLC bought a new position in shares of LifeMD in the second quarter worth approximately $3,828,000. Nuveen LLC purchased a new stake in shares of LifeMD during the first quarter valued at approximately $1,545,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of LifeMD during the second quarter valued at approximately $193,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in LifeMD in the 2nd quarter worth approximately $359,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.